NTLA
Overvalued by 149.7% based on the discounted cash flow analysis.
Market cap | $2.14 Billion |
---|---|
Enterprise Value | $2.11 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $-5.25 |
Beta | 2.38 |
Outstanding Shares | 103,732,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -4.31 |
---|---|
PEG | 13.86 |
Price to Sales | - |
Price to Book Ratio | 3.33 |
Enterprise Value to Revenue | 39.85 |
Enterprise Value to EBIT | -4.21 |
Enterprise Value to Net Income | -5 |
Total Debt to Enterprise | 0.06 |
Debt to Equity | 0.17 |
No data
No data
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus ?ik?nys . The company has partnerships with Novartis and Regeneron. Intellia Th...